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Introduction
Multiple myeloma (MM) is the second most common
hematologic cancer, with a higher incidence in elderly sub-
jects: 26% are aged 65-74 years, and 37% are older than 75
years.1 In the future, the prevalence of myeloma is likely to
increase due to the extended survival and the growing life
expectancy of the general population. Until the late 1990s, the
combination melphalan-prednisone (MP) had been the refer-
ence treatment for patients aged 65 years or over, and was
associated with a median survival of 29-37 months.2 The
introduction of novel agents, such as the proteasome
inhibitor bortezomib and the immunomodulatory drugs
(IMIDs) thalidomide and lenalidomide, has changed the treat-
ment paradigm of patients aged 65 years or over. In 6 ran-
domized trials, MP plus thalidomide (MPT) showed a pro-
gression-free survival (PFS) advantage in comparison with
MP,3-9 while overall survival (OS) benefit has not been consis-
tently reported. However, a recent meta-analysis has shown
a significant improvement in PFS and OS.10 The incidence of
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Thalidomide and bortezomib are extensively used to treat elderly myeloma patients. In these patients, treatment-
related side effects are frequent and full drug doses difficult to tolerate. We retrospectively analyzed data from 1435
elderly patients enrolled in 4 European phase III trials including thalidomide and/or bortezomib. After a median
follow up of 33 months (95%CI: 10-56 months), 513 of 1435 patients (36%) died; median overall survival was 50
months (95%CI: 46-60 months). The risk of death was increased in patients aged 75 years or over (HR 1.44,
95%CI: 1.20-1.72; P<0.001), in patients with renal failure (HR 2.02, 95%CI: 1.51-2.70; P<0.001), in those who
experienced grade 3-4 infections, cardiac or gastrointestinal adverse events during treatment (HR 2.53, 95%CI:
1.75-3.64; P<0.001) and in those who required drug discontinuation due to adverse events (HR 1.67, 95%CI; 1.12-
2.51; P=0.01). This increased risk was restricted to the first six months after occurrence of adverse events or drug
discontinuation and declined over time. More intensive approaches, such as the combination of bortezomib-
thalidomide, negatively affected outcome. Bortezomib-based combinations may overcome the negative impact of
renal failure. Age 75 years or over or renal failure at presentation, occurrence of infections, cardiac or gastrointesti-
nal adverse events negatively affected survival. A detailed geriatric assessment, organ evaluation and less intense
individualized approaches are suggested in elderly unfit subjects.
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ABSTRACT
any grade 3-4 non-hematologic adverse events (AEs) was
approximately 50% and thalidomide discontinuation rate
due to AEs varied from 33% to 45%, with higher inci-
dence in patients aged 75 years or over. MP plus borte-
zomib (VMP) showed both a PFS and OS advantage in
comparison with MP.11,12 In patients aged 75 years or over,
the efficacy of VMP was less evident: the 3-year OS was
shorter in comparison with patients aged under 75 years
(55% vs. 74%). The incidence of any grade 3-4 AEs was
91% and bortezomib discontinuation rate due to AEs was
34%. Both VMP and MPT are now considered the new
standards of care for newly diagnosed MM patients aged
65 years or over. Recently, the combination of bortezomib
and thalidomide with or without alkylating agents has
shown to be highly effective.13,14 The weekly administra-
tion of bortezomib reduced the incidence of AEs, especial-
ly peripheral neuropathy and gastrointestinal toxicity,
without affecting efficacy.13,14 Nevertheless, outcome was
mainly improved for patients aged under 75 years, while
limited advantage was reported in patients aged 75 years
or over.14 These data lead to the question as to whether
less toxicity may translate into more efficacy, especially in
unfit elderly patients. 
In this meta-analysis of individual patient data from 4
randomized trials, we assessed the influence of age, organ
damage, development of treatment-related AEs and drug
discontinuation as predictive factors of outcome in elderly
newly diagnosed MM patients receiving MP, MPT, VMP,
or bortezomib and thalidomide combination (bortezomib,
thalidomide and prednisone [VTP] or bortezomib, mel-
phalan, prednisone and thalidomide [VMPT]).
Design and Methods
Study design and treatments
Patients with newly diagnosed MM, not eligible for high-dose
therapy and autologous transplantation due to age (≥65 years) or
co-existing co-morbidities, enrolled in the GISMM-2001 MP versus
MPT, the HOVON 49 MP versusMPT, the GEM05MAS VMP ver-
sus VTP and the GIMEMA MM0305 VMP versus VMPT-VT phase
III trials were included in this meta-analysis. Details on treatment
regimens and results of these studies have been reported previous-
ly.5-7,13,14 All trials were approved by the institutional review board
at each of the participating centers. All patients gave written
informed consent before entering the study, which was performed
in accordance with the Declaration of Helsinki. Trials were regis-
tered at ClinicalTrials.gov or controlled-trials.com (numbers
NCT00232934, ISRCTN 90692740, NCT00443235 and
NCT01063179). 
Assessment
Individual patient data were collected for each patient enrolled
in the 4 trials at each co-ordinating center. All data were sent to a
central co-ordinating center, reviewed for consistency and com-
pleteness, and entered into a new database. The following data
available across all studies were collected for each patient: base-
line data [age, gender, creatinine value, International Staging
System, (ISS)]; date of death or date the patient was last known
to be alive; grade, type and date of AEs occurring during induc-
tion. AEs were graded according to National Cancer Institute
Common Terminology Criteria for Adverse Events, version 3.0.
OS was calculated from the time of symptomatic MM diagnosis
until the date of death or the date the patient was last known to
be alive.
Statistical analysis 
Patients were analyzed on an intention-to-treat basis for all
time-to-event end points. Times of observation were censored on
October 31st 2010. For this non pre-planned analysis, outcome and
AEs definitions were based on data common to all trials.
Descriptive statistics were used to characterize the incidence of
AEs and treatment discontinuation rate. In case of multiple grade
3-4 hematologic or grade 3-4 non-hematologic AEs, we considered
only the worst and the first occurred. Cumulative incidence of AEs
and treatment discontinuation were calculated considering death
from any cause as competing event. The proportional hazard
frailty model for the subdistribution was applied to evaluate the
effect of baseline factors (age, gender, ISS, serum creatinine, treat-
ment) on the cumulative incidence function of AEs and treatment
discontinuation accounting for heterogeneity across studies.15 OS
was estimated according to the Kaplan-Meier method and ana-
lyzed by univariate and multivariate Cox proportional hazards
models. The following variables were assessed for potential asso-
ciation with OS: age at diagnosis (≥75 vs. <75 years), gender, ISS
stages, baseline creatinine (≥2 vs. <2 mg/dL), treatment regimen
(MP/MPT/VMP/VTP plus VMPT). As ISS stage and baseline crea-
tinine data was not available for some patients, the category data
missing were created, and all patients were included in the analy-
sis. Grade 3-4 hematologic or grade 3-4 non-hematologic AEs dur-
ing induction or drug discontinuation were included in the Cox
regression models as time varying covariates. The inspection of
Schoenfeld residuals suggested a violation of proportional hazard
assumption for the hematologic AE, non-hematologic AE, and
drug discontinuation variables. Thus, the Cox models were fitted
dividing the post-event (hematologic AE, non-hematologic AE,
drug discontinuation) period into two periods: the first six months
after an event or after the start of follow up (for patients who did
not experience an event), and after the six months to the final fol-
low up. In order to account for clustering of patients within trials,
Cox shared frailty models were estimated. Statistical analysis was
performed by using STATA 11.0 (StataCorp LP, College Station,
TX, USA).
Results
Patients 
A total of 1435 patients were analyzed: 332 did not
receive novel agents (MP), 332 received MP plus thalido-
mide (MPT), 387 MP plus bortezomib (VMP), 384 MP plus
thalidomide and bortezomib (VTP/ VMPT). Baseline
demographics and disease characteristics are listed in
Table 1. Patients aged 75 years or over accounted for 36%
of the entire study population, and were equally distrib-
uted in the 4 groups. Distribution of patients according to
ISS staging was well balanced in all groups, except for a
lower frequency of ISS III in the MP group. The propor-
tion of patients with renal failure was higher in the MP
and MPT groups due to less stringent inclusion/exclusion
criteria of these protocols. 
Outcome, adverse events and drug discontinuation
After a median follow up of 33 months (IQR 26-41
months), the median OS was 50 months (IQR 24-.
months) and 64% of patients remained alive at three
years. At the date of last follow up, 513 out of the 1435
patients (36%) died. The reasons for death were: 389
(76%) disease progression, and 124 (24%) toxic effects.
The most frequent causes of toxicity-related death were
infections (8%), cardiac complications (8%), second pri-
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mary malignancies (2%) and venous thromboembolism
(VTE) (2%). Early toxic mortality rate, occurring within
the first three months from the start of treatment, was 2%
(34 patients). The incidence of any grade 3-4 hematologic
AEs was 563 of 1435 (39%) in the entire study population,
with a lower incidence in patients receiving MPT (33%)
compared with those receiving VMP (44%; P=0.002) or
VTP/VMPT (43%; P=0.009). The most frequent hemato-
logic AEs were neutropenia (27%), thrombocytopenia
(10%) and anemia (3%).
The incidence of any grade 3-4 non-hematologic AEs
was 412 of 1435 (29%) in the entire study population with
a higher incidence in patients receiving MPT (43%) com-
pared with those receiving VMP (24%) or VTP/VMPT
(32%). The most frequent non-hematologic AEs were
infections (10%), peripheral neuropathy (8%), cardiac
(6%) and gastro-intestinal complications (5%). Rate of
VTE was 3%. The cumulative incidences of all non-hema-
tologic AEs and of relevant AEs (infections, cardiac and
gastrointestinal AEs) increased over time reaching a
plateau after six months of therapy in all treatment groups
(Figure 1A and B). At six months, the cumulative incidence
of all non-hematologic AEs was 6.4% (95%CI: 3.7-9.0) in
the MP group, 23.8% (95%CI: 19.2-28.4) in the MPT
group, 19.5% (95%CI: 15.5-23.5) in the VMP group and
25.2% (95%CI: 20.8-29.6) in the VTP/VMPT group.
Similarly, the cumulative incidence of infections, cardiac
and gastrointestinal AEs was 4.8% (95%CI: 2.5-7.2) in the
MP group, 16.2% (95%CI: 12.2-20.2) in the MPT group,
12.1% (95%CI: 8.8-15.4) in the VMP group and 14.5%
(95%CI: 11.0-18.1) in the VTP/VMPT group.
Among patients not receiving novel agents (MP), drug
discontinuation for toxicity was reported in 4 of 332
patients (1%), mainly due to hematologic toxicity. Among
patients receiving novel agents, drug discontinuation for
toxicity was reported in 294 of 1103 patients (27%), with
a higher incidence in patients receiving MPT (35%) com-
pared with those receiving VMP (16%) or VTP/VMPT
(29%). The main reasons for thalidomide discontinuation
were peripheral neuropathy (9%), infections (4%), cardiac
(4%) and hematologic toxicities (4%). The main reasons
for bortezomib discontinuation were peripheral neuropa-
thy (6%), hematologic AEs (4%), infections (2%) and car-
diac AEs (3%). The cumulative incidences of drug discon-
tinuation increased over time reaching a plateau after eight
months of therapy in all treatment groups (Figure 1C). At
six months, the cumulative incidence of drug discontinua-
tion was 27.1% (95%CI: 22.3-32.0) in the MPT group,
9.0% (95%CI: 6.1-11.9) in the VMP group and 16.6%
(95%CI: 12.8-20.3) in the VTP/VMPT group. 
In a multivariable model, including several baseline
characteristics, a higher risk to develop a grade 3-4 hema-
tologic AE was detected for females (HR 1.32, 95%CI:
1.16-1.47; P<0.001), for patients with aggressive disease
defined by ISS 3 (HR 1.49, 95%CI: 1.11-2.00; P=0.007) and
for those with renal impairment (HR 1.51, 95%CI: 1.23-
1.86; P<0.001). The risk of 3-4 non-hematologic AEs was
increased by MPT treatment (HR 3.22, 95%CI: 1.20-8.64;
P=0.02), by VTP/VMPT treatment (HR 3.03, 95%CI: 1.26-
7.24; P=0.01) and by ISS 3 (HR 1.56, 95%CI: 1.09-2.23;
P=0.01).
Impact of baseline patient conditions on outcome 
The estimated 3-year OS was 68% in patients under 75
years and 57% in those aged 75 years or over (HR 1.44,
95%CI: 1.20-1.72; P<0.001). In patients aged 75 years or
over the risk of death was higher in patients receiving
VMP (HR 1.62, 95%CI: 1.04-2.52; P=0.03) and in those
receiving VTP/VMPT (HR 3.02, 95%CI: 1.86-4.90;
P<0.001) (Figure 2A). 
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Table 1. Baseline patients’ characteristics.
Variable ALL patients MP MPT VMP VTP/VMPT
(N=1435) (N=332) (N=332) (N=387) (N=384)
Age
Median years 72 72 72 72 72
IQR-years 69-76 69-76 69-76 69-76 69-77  
≥ 75 years – n (%) 518 (36) 117 (35) 114 (34) 140 (36) 147 (38)
Sex, n (%)
Male sex 739 (51) 185 (56) 177 (53) 188 (49) 189 (49)
Serum β2 microglobulin level, n (%)
>3.5 mg/L 700 (49) 144 (43) 155 (47) 199 (51) 202 (53)
Data missing 229 (16) 75 (23) 61 (18) 50 (13) 43 (11)
International Staging System stage, n (%)
I 283 (20) 51 (15) 55 (17) 92 (24) 85 (22)
II 586 (41) 157 (47) 127 (38) 143 (37) 159 (41)
III 271 (19) 14 (5) 71 (21) 94 (24) 92 (24)
Data missing 295 (20) 110 (33) 79 (24) 58 (15) 48 (13)
Creatinine level – n (%)
≥ 2 mg/dL 89 (6) 28 (8) 34 (10) 18 (5) 9 (2)
Data missing 5 (0.3) 4 (1) 1 (0.3) 0 0
Trials – n (%)
GISMM-2001 331 (23) 164 (49) 167 (50) 0 0
HOVON 49 333 (23) 168 (51) 165 (50) 0 0
GEM05MAS 260 (18) 0 0 130 (34) 130 (34)
GIMEMA MM0305 511 (36) 0 0 257 (66) 254 (66)
MP: melphalan and prednisone; MPT: melphalan, prednisone and thalidomide; VMP: melphalan, prednisone and bortezomib; VTP/VMPT: bortezomib, thalidomide,
prednisone/bortezomib, melphalan, prednisone, thalidomide.
The 3-year OS was 66% in patients without renal fail-
ure and 38% in those with renal failure (HR 2.02, 95%CI:
1.51-2.70; P<0.001). Renal failure did not increase the risk
of death in patients receiving VMP (HR 0.91, 95%CI: 0.22-
2.58; P=0.86) (Figure 2B). 
Impact of treatment-related AEs and drug 
discontinuation on outcome
The development of grade 3-4 hematologic AEs did not
increase the risk of death, both within the first six months
from the occurrence of AE (HR 1.24, 95%CI: 0.88-1.73;
P=0.21) and after this time point (HR 0.99, 95%CI: 0.80-
1.23; P=0.94). 
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Figure 1. Cumulative incidence of grade 3-4 AEs and of drug discon-
tinuation accounting for competing events (death and progressive
disease). (A) Cumulative incidence of grade 3-4 non-hematologic
toxicities.  (B) Cumulative incidence of grade 3-4 infections, cardiac
or gastrointestinal toxicities. (C) Cumulative incidence of drug dis-
continuation. 
Figure 2. Overall survival according to baseline patient conditions. (A)
Kaplan-Meier overall survival curves in patients younger or equal/older
than 75 years in whole population and within the different treatment
groups  in the forest plot (results are shown, on a log10 scale, for analy-
sis adjusted for gender, International Staging System and serum crea-
tinine). Interaction test (heterogeneity) P=0.0041. (B) Overall survival
in patients with or without renal failure (serum creatinine ≥ or < 2
mg/dL) in whole population and within the different treatment groups
in the forest plot (results are shown, on a log10 scale, for analysis
adjusted for gender, age and International Staging System. Interaction
test (heterogeneity) P=0.65. Hazard ratios higher than 1 indicate a
higher risk of death. The I bars represent 95% confidence intervals.
MP: melphalan and prednisone; MPT: melphalan, prednisone and
thalidomide; VMP: melphalan, prednisone and bortezomib; VTP/VMPT:
bortezomib, thalidomide, prednisone/ bortezomib, melphalan, pred-
nisone, thalidomide.
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The development of grade 3-4 non-hematologic AEs
increased the risk of death within the first six months
from the occurrence of AEs (HR 1.82, 95%CI: 1.29-2.57;
P=0.001) (Figure 3A), whereas after this time point the risk
of death was similar to that of patients who did not expe-
rience non-hematologic AEs (HR 0.86, 95%CI: 0.67-1.10;
P=0.22). The occurrence of grade 3-4 cardiac AEs (HR
3.19, 95%CI: 1.79-5.71; P<0.001), infections (HR 2.94,
95%CI: 1.93-4.46; P<0.001) or gastrointestinal AEs (HR
2.30, 95%CI: 1.14-4.67; P=0.02) were the most significant
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VMP 1.27 (0.44 to 3.69) 0.66
VTP/VMPT 2.17 (1.00 to 4.69) 0.05
HR 95% CI P
All 2.53 (1.75 to 3.64) <0.001
MP 1.46 (0.59 to 3.63) 0.41
MPT 2.96 (1.71 to 5.15) <0.001
VMP 2.73 (1.03 to 7.24) 0.04
VTP/VMPT 2.77 (1.18 to 6.51) 0.02
All 1.62 (1.12 to 2.51) 0.01
MP NA NA
MPT 1.14 (0.60 to 2.17) 0.69
VMP 2.29 (0.88 to 5.95) 0.009
VTP/VMPT 3.44 (1.64 to 7.23) 0.001
Figure 3. Impact of treatment-related complications on overall sur-
vival. (A) Impact of grade 3 to 4 non-hematologic toxicity in whole
population and within the different treatment groups within the first
6 months after the occurrence of event  in the forest plot (results
are shown, on a log10 scale, for analysis adjusted for age, gender,
International Staging System and serum creatinine). Interaction test
(heterogeneity) P=0.79. (B) Impact of grade 3 to 4 infections, car-
diac, or  gastrointestinal adverse events in whole population and
within the different treatment groups within the first 6 months after
the occurrence of event  in the forest plot (results are shown, on a
log10 scale, for analysis adjusted for age, gender, International
Staging System and serum creatinine). Interaction test (heterogene-
ity) P=0.52. (C) Impact of drug discontinuation due to grade 3-4
adverse events in whole population and within the different treat-
ment groups within the first 6 months after the occurrence of event
in the forest plot (results are shown, on a log10 scale, for analysis
adjusted for age, gender, International Staging System and serum
creatinine). Interaction test (heterogeneity) P=0.14. Hazard ratios
higher than 1 indicate a higher risk of death. The I bars represent
95% confidence intervals.  MP: melphalan and prednisone; MPT:
melphalan, prednisone and thalidomide; VMP: melphalan, pred-
nisone and bortezomib; VTP/VMPT: bortezomib, thalidomide, pred-
nisone/ bortezomib, melphalan, prednisone, thalidomide.
predictors of shorter OS. Pooled together, they increased
the risk of death within the first six months (HR 2.53,
95%CI: 1.75-3.64; P<0.001) (Figure 3B), whereas after this
time point the risk of death was similar to that of patients
who did not experience this type of AEs (HR 0.86, 95%CI:
0.67-1.10; P=0.22). The increased risk of death associated
with the development of cardiac AEs, infections and gas-
trointestinal AEs was similar in patients receiving MPT,
VMP or VTP/VMPT. By contrast, the occurrence of VTE
was not associated with shorter OS (HR 1.02, 95%CI:
0.32-3.19; P=0.97) and peripheral neuropathy was associ-
ated with improved OS (HR 0.27, 95%CI: 0.07-1.10;
P=0.07). 
Drug discontinuation due to AEs was correlated with
increased risk of death within the first six months (HR
1.67, 95%CI: 1.12-2.51; P=0.01) (Figure 3C), whereas after
this time point the risk of death was similar to that of
patients who did not discontinue treatment (HR 0.93,
95%CI: 0.70-1.23; P=0.61). In patients who discontinued
treatment, the risk of death was higher among patients
receiving VMP (HR 2.29, 95%CI: 0.88-5.95; P=0.09) or
VTP/VMPT (HR 3.44, 95%CI: 1.64-7.23; P=0.001) (Figure
3C). 
Multivariate analysis
A Cox proportional hazards regression model is shown
in Figure 4. Advanced age (≥75 years) (HR 1.36, 95%CI:
1.14-1.63; P=0.001), renal failure (creatinine level ≥ 2
mg/dL) (HR 1.59, 95%CI: 1.18-2.16; P=0.003), and the
occurrence of grade 3-4 non-hematologic AEs (HR 1.72,
95%CI: 1.19-2.47; P=0.004) (especially cardiac complica-
tions: HR 2.61, 95%CI: 1.49-4.60, P=0.001; and infections:
HR 2.46, 95%CI: 1.58-3.82, P<0.001) as well as drug dis-
continuation due to toxicity (HR 1.61, 95%CI: 1.03-2.50;
P=0.03) were the variables associated with a shorter OS,
regardless of staging and treatment administered. 
Discussion 
In this study, individual patient data from 1435 patients
with newly diagnosed MM who received MP, either alone
or in combination with thalidomide and/or bortezomib,
were analyzed. In multivariate analysis, the advanced age
(≥75 years), renal failure, occurrence of severe cardiac AEs,
infections, gastrointestinal AEs and drug discontinuation
were predictive of shorter survival. Several studies have
analyzed the prognostic role of age and renal failure,16,25
but no study has evaluated the impact of AEs and drug
discontinuation on long-term outcome. The strength of
this analysis lies in the size and the similarity of the
patient population, derived from 4 of the largest European
randomized controlled trials. Furthermore, our study
focused on the two reference treatment regimens for eld-
erly MM patients: MPT and VMP.
In 10,549 patients with newly diagnosed MM, older
patients had more adverse prognostic factors and shorter
survival than the younger ones.26 In a recent meta-analysis
of individual patient data from 1682 patients enrolled in 6
randomized trials comparing MP with MPT, as well as in
the VISTA study comparing MP with VMP, and in the
MM015 study comparing MP with MP plus lenalidomide
with or without lenalidomide maintenance, survival was
worse in patients aged 75 years or over.10,12,27 Life expectan-
cy changes as one gets older: it is about 15 years in
patients under 75 years of age and ten years in those who
are older.28 Nevertheless, in our study, older patients had a
higher risk of death when they were treated with a more
aggressive treatment. Age 75 years or over increased the
risk of death by 1.62-fold in patients receiving VMP, 3.02-
fold in those receiving VTP/ VMPT, but only marginally in
patients receiving MP or MPT. Combination including
both bortezomib and thalidomide should be used with
caution in elderly patients. Some practical issues, such as
costs and intravenous injection of bortezomib, together
with our results further support the use of oral combina-
tions including immunomodulatory drugs (IMIDs) in
patients with more advanced age. In the future, the avail-
ability of new oral proteasome inhibitor or subcutaneous
administration could eventually modify these indica-
tions.29,30
Aging is associated with a reduction in cardiac, renal,
and gastric functions, hepatic mass, blood flow, and bone
marrow status.31-35 All of these changes affect the pharma-
cokinetics and pharmacodynamics of drugs, increase toxi-
city, and decrease the clinical efficacy and the tolerability
of treatments. 
Renal failure is a common feature of MM and has been
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Male
Age ≥ 75 years
Serum creatinine ≥ 2 mg/dL
Grade 3 to 4 hematologic AEs*
Grade 3 to 4 non-hematologic AEs*
1.13 (0.95 to 1.35) 0.17
1.36 (1.14 to 1.63) 0.001
1.59 (1.18 to 2.16) 0.003
1.24 (0.88 to 1.75) 0.21
1.72 (1.19 to 2.47) 0.004
2.61 (1.49 to 4.60) 0.001
2.46 (1.58 to 3.82) <0.001
1.89 (0.92 to 3.89) 0.08
1.14 (0.42 to 3.10) 0.79
0.29 (0.07 to 1.18) 0.08
1.61 (1.03 to 2.50) 0.03
0,01 0,1 1 10
Lower mortality Higher mortality
Drug discontinuation due to AEs*
Cardiac AEs*
Infective AEs*
Gastrointestinal AEs*
Venous thrombosis AEs*
Peripheral neuropathy AEs*
HR 95% CI P
Figure 4. Hazard ratios for deaths for any
cause, according to presence (vs.
absence) of risk factors, treated as time-
dependent variables. Results are shown
on a log10 scale, for analysis adjusted for
treatment and International Staging
System (multivariate analysis). Hazard
ratios higher than 1 indicate a higher risk
of death. The I bars represent 95% confi-
dence intervals. AEs: Adverse Events.
*Impact on overall survival within the
first 6 months after the occurrence of the
event.
associated with inferior survival.35-37 Thalidomide and
bortezomib pharmacokinetics are not affected by renal
impairment and no dose reduction is required. In the MPT
meta-analysis, the benefit of MPT was not evident in
patients with renal failure.13 By contrast, in the VISTA trial,
the outcome of patients treated with VMP was not affect-
ed by renal impairment.23 Our data showed that creatinine
2 mg/dL or over increased the risk of death by 1.53-fold in
patients receiving MPT and by 1.82-fold in those receiving
VMPT/VTP, while it did not increase the risk of death in
patients receiving VMP. Our results should be considered
with caution, due to the small number of patients with
creatinine 2 mg/dL or over; on the other hand they sup-
port the recent consensus statement on behalf of the
International Myeloma Working Group that recommends
VMP as first-line treatment in elderly patients with renal
failure.38
Before the introduction of novel agents, early toxic
death had reached 10% in newly diagnosed MM patients
receiving conventional chemotherapy.37 Early mortality is
often due to combined effect of active disease and co-mor-
bidities. Our analysis showed that the use of novel agents
decreased the early toxic death risk to 2%. This may be
due to a quick reduction in tumor load. Nevertheless, the
occurrence of grade 3-4 non-hematologic AEs is associated
with a worse prognosis. The impact was different among
the different types of toxicities. Infections, cardiac and
gastrointestinal complications had the worst impact on
survival, regardless of the type of therapy. Sub-clinical
organ dysfunction may emerge as clinically relevant after
the organ stress induced by MM treatment. These data
further suggest the need for a detailed organ evaluation
and geriatric assessment before starting any treatment in
elderly subjects. In our study, VTE was not associated
with shorter survival. Similar results were reported in a
retrospective study on 668 newly diagnosed patients
receiving chemotherapy with or without thalidomide39
and in a retrospective study on 353 relapsed or refractory
patients receiving lenalidomide and high-dose dexametha-
sone.40 In our analysis, peripheral neuropathy was associ-
ated with improved survival. A sub-analysis of the VISTA
trial showed a higher response rate and longer time-to-
progression in patients who experienced peripheral neu-
ropathy compared with those who did not.41-43 Responding
patients are likely to continue therapy for a longer period
of time than non-responding patients. They receive higher
cumulative doses which may explain the higher frequency
of peripheral neuropathy. Recently, an interaction
between myeloma-related factors and the patient's genet-
ic background in the development of treatment-induced
peripheral neuropathy has been shown.44
Drug discontinuation due to AEs was associated with a
shorter survival, probably because of lower cumulative
delivered-dose. The cumulative delivered-dose may be
one of the factors affecting outcome. The outcome of
patients aged 75 years or over receiving melphalan, pred-
nisone and lenalidomide was worse than younger
patients, due to the higher discontinuation rate and subse-
quent lower cumulative dose-intensity of both melphalan
and lenalidomide.27 The once-weekly schedule of borte-
zomib significantly reduced the incidence of grade 3-4
hematologic and non-hematologic AEs and the rate of
drug discontinuation without having a negative impact on
outcome.13,45 Indeed, the cumulative delivered-dose of
bortezomib was similar for both twice- and once-weekly
schedules of bortezomib. This finding may underline the
need to deliver the appropriate dose intensity in all patient
sub-groups in order to avoid drug discontinuation and loss
of efficacy. On the other hand, the inability to tolerate less
drug may mirror a weaker resistance of the host to toxic
injuries, which per se may be the main reason for shorter
survival. In the future, a more precise definition of organ
dysfunction (with appropriate co-morbidity scores) and
frailty (with specific geriatric assessment) should become
mandatory to immediately define a gentler, less dose-
intense approach, instead of intervening later, after the
occurrence of too many unacceptable toxicities. Patients
with at least one risk factor such as age 75 years or over,
cardiac, pulmonary, renal or hepatic organ dysfunction,
frailty, or occurrence of grade 3-4 non-hematologic AEs
during treatment, should be considered for a reduced
dose-intensity treatment strategy.46
In conclusion, we showed that advanced age, renal fail-
ure, occurrence of infections, cardiac, or gastrointestinal
grade 3-4 AEs have a significant negative impact on sur-
vival outcomes of elderly patients. Future trials focused on
optimizing MM treatment regimens for both fit and unfit
elderly adults are urgently needed to define tailored, ‘per-
sonalized’ therapy for this large patient population.
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